ALBIO — Biosynex SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Biosynex SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	FAS	FAS	FAS	FAS	FAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	154	383	197	93	101
Cost of Revenue
Gross Profit	69.3	206	102	49.1	57.4
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	109	243	164	128	139
Operating Profit	44.7	140	32.9	-35.1	-37.9
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	44.4	140	29.8	-38.2	-44.7
Provision for Income Taxes
Net Income After Taxes	32.2	107	21.2	-35.6	-43.3
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	31.4	104	15.6	-37.3	-43.3
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	31.4	104	15.6	-37.1	-43.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.87	7.77	2.06	-2.95	-2.55
Dividends per Share